Sigyn Therapeutics, Inc. (OTCQB: SIGY) CEO Jim Joyce released a shareholder update on March 13, 2026, detailing the company's strategic initiatives, including a potential merger with a Nasdaq-listed company facing delisting risk and the sale of certain assets. The update also highlighted the therapeutic potential of Sigyn's CardioDialysis platform for cardiovascular disease and sepsis.
Joyce, who previously founded Aethlon Medical and led the development of the Hemopurifier, emphasized that Sigyn's CardioDialysis targets cholesterol-transporting lipoproteins and inflammatory molecules, designed for use on existing dialysis machines at over 7,500 U.S. clinics. This contrasts with limited availability of lipoprotein apheresis at fewer than 60 specialized centers. CardioDialysis also reduces sepsis-inducing bacterial toxins, including endotoxin, positioning it as a potential therapy for sepsis, which currently has no approved treatment.
The CEO noted that Sigyn became public through a merger with an OTC company but failed to execute an uplist to Nasdaq due to a regulatory catch-22 involving SEC and Nasdaq requirements. As a result, the company is exploring a merger with a Nasdaq-listed firm at risk of not meeting the $5 million minimum market value of listed securities requirement. Joyce also referenced a January 15th shareholder update detailing strategies to reduce shareholder dilution.
Joyce encouraged shareholders to follow Spectral Medical, whose PMX device for sepsis has advanced through clinical studies. He concluded by stating the company has 2,330,042 shares outstanding as of March 11, 2026.
